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Abstract
Introduction—Rotavirus vaccines have significantly decreased the burden of diarrheal diseases 
in countries that have introduced them into their immunization programs. In some studies, there 
has been a small association between rotavirus vaccines and intussusception in post-marketing 
surveillance, high-lighting the importance of tracking incidence before and after vaccine 
introduction. The objective of this study was to describe the epidemiology of intussusception 
among Bangladeshi children pre-vaccine introduction.
Methods—We conducted active, hospital-based surveillance for intussusception at 7 tertiary care 
hospitals with pediatric surgical facilities during July 2012 to September 2016. Hospitalized 
children under 2 years of age were identified according to Brighton Collaboration level 1 criteria 
for intussusception. The frequency and proportion of intussusception among overall surgical 
admissions, as well as the demographic and clinical information of the cases is described.
Results—Overall 153 cases of intussusception among children <2 years-old were identified at 
participating sites over the enrolment period, confirmed by Level 1 Brighton criteria. These cases 
represented 2% of all surgical admissions under 2 years of age. One hundred twelve cases (73%) 
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were male; the median age was 7 months; and the median duration of hospitalization was 7 days. 
One hundred forty-six (95%) children with intussusception required surgery, and 11 (7%) died.
Conclusions—Confirmed cases of intussusception represented nearly 2% of pediatric surgical 
admissions at tertiary referral centers in Bangladesh during the study period and 7% of children 
with intussusception died. Given the high burden of rotavirus disease in Bangladesh, vaccine 
introduction is warranted, however, further studies after introduction of rotavirus vaccine are 
necessary to determine any association between vaccine and intussusception in this setting.
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1. Introduction
Since their introduction in 2006, rotavirus vaccines have decreased the morbidity and 
mortality of diarrheal disease in many countries that have included them in their national 
immunization programs [1–4]. Evidence from post-licensure studies continues to 
demonstrate decreases in rotavirus-related morbidity and mortality in these countries, 
however a low-level risk of intussusception has also been described following rotavirus 
vaccination [5–8].
Intussusception is a rare emergency medical condition that occurs in the absence of rotavirus 
infection, in which intestinal blockage results from part of the intestine folding into an 
adjacent portion. While spontaneous self-resolution of small-bowel intussusceptions has 
been reported [9,10], for the majority of intussusceptions, if treatment is not sought, this 
blockage can go on to create an obstruction, compromising blood circulation to involved 
portions of intestine. Intussusception cases occur most commonly in infants, with cases 
peaking between 4 and 6 months of age. The estimated global rate of intussusception is 74 
cases per 100,000 children under 1 year of age, ranging between 9 and 328 case per 100,000 
depending on geographic location [11]. The majority of cases, particularly among infants, 
are idiopathic [12].
A nearly 30-fold increased risk of intussusception was observed in the first 3–14 days after 
the first dose of the rhesus reassortant tetravalent vaccine Rotashield (RRV-TV; Wyeth 
Vaccines) following its introduction in the US in the late 1990s [13]. Subsequently, 
Rotashield was removed from the market and there was close vigilance for intussusception 
during clinical trials for two subsequently available rotavirus vaccines, the pentavalent 
Rotateq (RV5, Merck) and the monovalent Rotarix (RV1, GlaxoSmithKline) vaccines. 
Though intussusception was not associated with vaccine in the large-scale pre-licensure 
clinical trials [14,15] of RV5 and RV1, both vaccines were shown to be associated with a 
mild increased risk of intussusception (1–6 excess cases per 100,000 vaccinated children) in 
post-marketing surveillance in several high and middle income countries [5–8].
Post-licensure data on risk of intussusception with rotavirus vaccination from Asian 
countries data is lacking. The risk profile could differ in developing versus developed 
countries because of differences in vaccine performance as well as differences in the 
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epidemiology of intussusception. As Bangladesh prepares to introduce rotavirus vaccine into 
its national immunization program in the next 1–2 years, it is important to characterize the 
background epidemiology of intussusception and to plan for intussusception surveillance 
after vaccine introduction. This analysis aimed to describe the frequency, epidemiology and 
clinical characteristics of intussusception among children <2 years hospitalized at sentinel 
sites across Bangladesh.
2. Methods
2.1. Surveillance sites
In July 2012, an active, hospital-based rotavirus and intussusception surveillance system has 
begun in Bangladesh in collaboration with The Institute of Epidemiology, Disease Control 
and Research (IEDCR) under the Ministry of Health and Family Welfare and icddr,b. 
Geographically, Bangladesh is subdivided in seven different regions, and we aimed to have 
one hospital included per region. Sites began enrolment in three stages (Fig. 1), first in three 
sites (Dhaka, Rajshahi and Sylhet) in July 2012 followed by two sites (Rangpur and 
Chittagong) in February 2013 and in two additional sites (Khulna and Barisal) in August 
2013 (Table 1). These hospitals were chosen based on the presence of surgical facilities and 
because they have high numbers of admissions for pediatric surgeries. The original site in 
Rangpur closed during July–December 2016 due to closer of pediatric surgery ward and so 
an alternative tertiary hospital in the area was added in its place in January 2016 (see Table 
2).
2.2. Case definition and enrolment
Field surveillance staff reviewed hospitalization and radiology logbooks weekly and met 
with surgical and radiological staff daily to identify suspected intussusception cases among 
children <2 years of age. Once a potential intussusception case was identified, a surveillance 
physician reviewed the medical record to determine if the child met the case definition for 
confirmed intussusception as per Brighton Collaboration Level 1 criteria, (Box 1) [16]. 
Because autopsies are not commonly done in Bangladesh, autopsy criteria were not used for 
the detection cases. Brighton Collaboration Level 2 and 3 criteria were included to the case 
definition for the surveillance system beginning in December 2014 to enroll clinically 
suspected cases of intussusception.
Box 1
Level 1, 2, or 3 Brighton Collaboration criterion (i.e. “definite”, “probable”, 
and “possible” cases, respectively) for the diagnosis of intussusception 
among hospitalized children aged <2 years
Level 1 of diagnostic certainty (or “definite”)
• Surgical criteria:
– Demonstration of invagination of the intestine at surgery; and/or
• Radiological criteria:
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– Demonstration of invagination of the intestine by either air or liquid 
contrast enema; or
– Demonstration of an intra-abdominal mass by abdominal ultrasound 
with specific characteristic features (target sign or doughnut sign on 
transverse section and a pseudo kidney or sandwich sign on 
longitudinal section), that is proven to be reduced by hydrostatic 
enema on post-reduction ultrasound; and/or
• Autopsy criteria:
– Demonstration of invagination of the intestine at autopsy
Level 2 of diagnostic certainty (or “probable”)
• Clinical criteria:
Two major criteria or one major criterion and three minor criteria (see below)
Level 3 of diagnostic certainty (or “possible”)
• Clinical criteria:
Four or more minor criteria (see below)
Major criteria:
1. Evidence of intestinal obstruction, by either of the following: Bile-
stained vomiting and either abdominal distention or abnormal or 
absent bowel sounds, or plain radiograph of abdomen showing 
dilated bowel loops and fluid levels.
2. Features of intestinal invagination with any of the following: 
Abdominal mass, rectal mass, rectal prolapse, visible 
intussusceptum or soft-tissue mass observed on plain radiograph 
film, ultrasound, or CT scan.
3. Evidence of intestinal vascular compromise or venous congestion 
with any of the following: Rectal bleeding or stool containing “red 
currant jelly” material or blood observed on rectal examination
Minor criteria:
1. Predisposing factors (age <1 year and male)
2. Abdominal pain
3. Vomiting
4. Lethargy
5. Pallor
6. Hypovolemic shock
7. Plain radiograph of abdomen showing nonspecific abnormalities
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Upon enrolment, demographic information, rotavirus vaccination history, clinical 
information, including diagnostic procedures and outcome of hospitalization, were collected 
from the parents or caregivers and hospital records using a standard questionnaire. Each 
child’s rotavirus vaccination status was ascertained by querying parents because although 
rotavirus vaccines are not routinely available in Bangladesh, they are available in the private 
market and have been used in clinical trials in some regions. In addition, detailed contact 
information of enrolled children’s families was collected to ascertain outcomes at 30 days 
following discharge by telephone and in-person visit. In November 2015, a new question 
was added to the questionnaire inquiring about the date of onset of symptoms.
2.3. Analysis
We analyzed confirmed cases of intussusception. Aggregate numbers of admissions to the 
pediatric surgical ward and deaths among children under 2 years were extracted from 
hospital logbooks to obtain denominators for analyses.
We described the clinical characteristics of children admitted with intussusception and the 
frequency of intussusception-associated hospitalizations by site. To estimate the proportion 
of intussusception-associated hospitalizations among total pediatric surgical hospitalizations 
of children under two years, the overall number of children under two years admitted for 
intussusception was divided by the total number of pediatric surgery admissions of children 
under two years during the surveillance period.
2.4. Ethical considerations
We obtained written informed consent from the enrolled children’s parents or guardians. The 
study protocol was reviewed and ethics approval obtained from the ethical review committee 
of icddr,b.
3. Results
From July 2012 to September 2016, we identified 153 children with confirmed Brighton 
level 1 intussusception, accounting for ~2% of 8346 children <2 years of age admitted for 
pediatric surgery (Table 1). The proportions of confirmed cases of intussusception among 
children admitted to pediatric surgical wards in the seven divisions ranged from 0 to 3.6%. 
Most patients with intussusception (91%) were <1 year of age (Fig. 2) with a median age of 
7 months (IQR = 5–9); 65% were 6–11 months and 3% were ≤3 months old. Most children 
with intussusception were male (73%). Among the confirmed intussusception cases, 15 
(10%) were diagnosed via ultrasound only and the rest were diagnosed during surgery with 
or without ultrasonagraphy. The majority of children were treated surgically (95%), and 58 
(39%) required bowel resection. Children were hospitalized for a median of 7 days (IQR = 
5–9) and no recurrences of intussusception were identified. None of the children with 
intussusception had a history of rotavirus vaccination. Intussusception cases were reported 
year-round with no evidence of seasonality (Fig. 3).
Eleven deaths (7%) were reported among the 153 children hospitalized with confirmed 
intussusception. During this surveillance period, 511 children <2 years age died due to any 
surgical procedure; of whom, 11 (2%) died due to intussusception. All 11 children who died 
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underwent surgical treatment; 8 died during hospitalization (3 due to circulatory shock and 5 
due to septicemia) and 3 died following discharge from the hospital. The deaths of the three 
children who left the hospital before treatment was completed were confirmed by follow up 
with their parents but unfortunately, we failed to ascertained the cause of death. Of the 59 
children with confirmed Level 1 intussusception enrolled after the addition of the question 
about date of onset of symptoms, the median duration of symptoms prior to admission was 3 
(range: 0–17) days; the time from onset to admission was shorter for the 2 children who died 
(median: 1.5 day; range 1–2 days) than for the 57 children who survived (median 3 days; 
range 0–17 days, p = 0.17), though these findings were not statistically significant.
4. Discussion
We describe the results of over four years of active hospital-based surveillance for 
intussusception in all 7 seven divisions in Bangladesh. The proportion of males diagnosed 
with intussusception was higher than that of females, which is consistent with other reported 
data on intussusception cases occurring in the absence of rotavirus vaccine administration 
from both high and low income settings [17–22]. The reasons for this male predominance 
are unclear but may reflect greater healthcare seeking for male children with 
intussusception, genetic factors or both.
The age distribution of intussusception cases was similar to that seen in other studies in Asia 
which have reported that the majority of cases were unrelated to vaccination, occurred 
between 6 and 11 months of age and, importantly, that very few cases among those under 14 
weeks of age [18,19,23]. In studies showing an association of intussusception with rotavirus 
vaccine, the risk has been noted primarily in the first week after vaccine administration 
[5,6,24]. In subjects in this study, none of whom had been previously vaccinated, no cases 
were identified among children less than 2 months of age, suggesting that targeting children 
<3 months for vaccination may avoid vaccine administration during the peak risk period for 
naturally occurring intussusception. Currently, the World Health Organization recommends 
that the first rotavirus vaccine dose should be administered as soon as possible after 6 weeks 
of age, with subsequent doses (1 for monovalent and 2 for pentavalent) administered at 4 
weeks intervals [25].
The case-fatality rate among children with intussusception was 7% in this study. Few 
published data on intussusception fatality rates from countries in Asia region have been 
reported which can be used to comparison with findings from this studies. Two studies 
conducted in Vietnam found a lower rate, with one describing 869 identified intussusception 
cases (annual rate 296/100,000 infants) in a three year period, and no deaths [11,18]. One 
reason for this discrepancy may be that a greater proportion of children with intussusception 
in the current study were treated surgically than in the Vietnam study, and more than one-
third of our surgically-treated cases had bowel resections. It is also possible, that there were 
longer delays between onsets of symptoms to admission among cases in this study compared 
than in the studies from Vietnam. In one of the studies from Vietnam, the median onset of 
symptoms to admission was 5 h [18], compared to 3 days in this study. It is possible that in 
our study, there was a greater severity of disease on admission due to the longer time 
between onset and admission, which could explain higher rates of surgical treatment and 
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death in our study. Indeed, case fatality rates as high as 28–34% have been reported in some 
studies conducted in Africa, where delays in presentation are common and the predominant 
mode of treatment is surgical [26]. An additional possible reason for the higher case-fatality 
rate observed in our study may be because it was a prospective study, which made it easier to 
follow-up with patients after discharge and determine their outcomes.
This analysis was subject to several limitations. We were unable to capture children who 
died on arrival or soon after arriving at the hospital and those who did not present to a 
hospital for care. Some sites did not identify any cases, which may indicate a lack of 
sensitivity of the surveillance system or interruptions in the availability of surgical resources. 
Another limitation was the lack of sentinel site catchment data, as such we were unable to 
report intussusception incidence rates to which post-vaccine introduction rates could be 
compared. A prior study from Bangladesh with both retrospective and prospective analyses, 
reported incidence rates of probable and possible intussusception in rural areas [27]. In this 
study, the retrospective surveillance estimated that the incidence of possible and probable 
intussusception ranged from 0 to 17.8 and 17.7–81.7 cases per 100,000 children under 2 
years, respectively, whereas their prospective surveillance, estimated that the incidence of 
intussusception ranged from 0 to 18.7 and 0–9.7 cases per 100,000 population, respectively.
5. Conclusion
This study provides valuable information on the baseline epidemiology of childhood 
intussusception in Bangladeshi children prior to the introduction of rotavirus vaccination. 
Given the noted differences in case identification by site, the rarity of intussusception, and 
the small additional risk conferred by administration of rotavirus vaccine seen in other 
settings, further research is necessary to assess both health care utilization and post-vaccine 
introduction intussusception risk. Given the differences noted in identification of 
intussusception cases across sites, understanding health care utilization in these catchment 
areas is worth pursuing to refine the sensitivity of the surveillance system. To assess post-
vaccine introduction risk, use of the case series approach, which will not require comparison 
of incidence rates, after vaccine introduction is warranted, as well as continued high-quality 
surveillance on diarrheal burden using a hospital-based rotavirus surveillance platform. Both 
of these will allow determination of benefits and risks of rotavirus vaccines in Bangladesh.
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Fig. 1. 
Locations of sentinel hospitals where intussusception surveillance was conducted in 
Bangladesh, July 2012–September 2016. H represents the location of hospital within each 
division.
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Fig. 2. 
Age distribution of Intussusception associated hospitalizations among children <2 years of 
age (N = 153) at 8 sentinel hospitals in Bangladesh, July 2012–September 2016.
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Fig. 3. 
Hospitalization by month for Intussusception (N = 153) among children aged <2 years at 
sentinel hospitals in Bangladesh, July 2012–September 2016.
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Table 1
Intussusception (IS) hospitalizations among children aged <2 years, by site in Bangladesh, July 2012 – 
September 2016.
Location of sentinel 
sites
Number of children 
admitted for pediatric 
surgery
Number of suspected 
IS cases
Number of confirmed 
IS cases
% of all pediatric surgical 
cases (95% CI)
Dhaka 1211 15 10 0.83 (0.40–1.51)
Rajshahi 3009 177 94 3.12 (2.53–3.81)
Sylhet 689 31 25 3.63 (2.36–5.31)
Chittagong 131 6 4 3.10 (0.84–7.63)
Rangpura 20 0 0 0
Khulna 667 0 0 0
Barisal 1941 45 17 0.88 (0.51–1.40)
Rangpurb 678 8 3 0.44 (0.09–1.39)
All locations 8346 282 153 1.83 (1.66–2.14)
a
First site.
bSecond site.
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Table 2
Characteristics of Children Aged <2 Years Hospitalized with Intussusception (IS) at 8 Sentinel Hospitals in 
Bangladesh, July 2012–September 2016.
Characteristic Intussusception cases N=153 (%)
Age, median months (range) 7 (3–23)
Female 41 (27)
Brighton Collaboration criteria (N=160)
 Definite or Level 1 153 (95)
 Probable or Level 2 6 (4)
 Possible or Level 3 1 (1)
Method of diagnosis of Level 1IS cases
 Only ultrasound 15 (10)
 Only during surgery 18 (12)
Both ultrasound and during surgery 120 (78)
History of rotavirus vaccination 0
Length of hospital stay, median days (range) 7 (0348)
Treatmenta
 None, spontaneously resolved 5 (5)
Surgery 146 (95)
Bowel resected during surgeryb 58 (39)
Recurrence after treatment 0 (0)
Deaths
 During hospitalization 8 (5)
 After discharge 3 (2)
Note: Data are number (%) of children, unless otherwise indicated.
a
Before treatment started, one children with intussusception were transferred to another hospital and one died.
b
n = 146.
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